05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; medicinal drinks; lacteal flour
for babies; nutritional supplements; dietary supplements;
food supplements; nutritional and dietary supplements formed
and packaged as bars; dietary supplement drinks; dietary
supplement drink mixes; dietetic beverages adapted for
medical purposes; dietetic foods adapted for medical
purposes; beverages for babies; food for babies.
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
05 - Produits pharmaceutiques, vétérinaires et hygièniques
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations; diagnostic preparations for
medical purposes; diagnostic reagents for medical use. Providing medical information; medical analysis services for
diagnostic and treatment purposes provided by medical
laboratories; pathological testing for diagnostic or
treatment purposes.
6.
METHODS OF DISPERSING ARIPIPRAZOLE INJECTABLE PREPARATIONS
The present disclosure is directed to methods of dispersing injectable preparations comprising aripiprazole or a salt thereof. Methods of enhancing slidability of containers comprising long-acting injectable preparations comprising aripiprazole or a salt thereof, the methods comprising dispersing ingredients comprised in the preparations before administration, aripiprazole injectable preparations to be administered after the dispersion, methods of administration thereof, and use thereof are provided.
Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.
A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p. ex. carbazole
The present invention relates to a microorganism belonging to the genus Akkermansia, having a 16S rRNA gene comprising a nucleotide sequence etc. having homology of more than 98.0% to a nucleotide sequence set forth in SEQ ID NO: 3, having NOD2 agonistic activity, having assimilability to D-mannitol, being a Gram-negative, anaerobic bacterium with a spherical to short rod-shaped form, being negative in an oxidase test, and being positive in a catalase test, and a microorganism for activating NOD2, activating immunity, etc., comprising the microorganism as an active ingredient.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of central nervous system diseases and disorders; pharmaceutical preparations for the treatment of schizophrenia; pharmaceutical preparations for the treatment of cognitive disorders; pharmaceutical preparations for the treatment of major depressive disorder; pharmaceutical preparations for the treatment of generalized anxiety disorder.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of central nervous system diseases and disorders; pharmaceutical preparations for the treatment of schizophrenia; pharmaceutical preparations for the treatment of cognitive disorders; pharmaceutical preparations for the treatment of major depressive disorder; pharmaceutical preparations for the treatment of generalized anxiety disorder.
A method for detecting conjunctival diseases such as conjunctival MALT lymphoma, and an aging biomarker that serves as an indicator of the aging state of a subject are provided. The method for detecting conjunctival diseases comprises a step of comparing a microbial community structure of a microbiota in an ocular surface tissue specimen sampled from a healthy person with a microbial community structure of a microbiota in an ocular surface tissue specimen sampled from a subject to determine that the ocular surface tissue specimen of the subject has an indication of the conjunctival diseases. The aging biomarker comprises bacterial species which belongs to the Corynebacteriaceae family or the Propionibacteriales family in an ocular surface tissue.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
Disclosed are a method for producing an aripiprazole suspension, wherein the aripiprazole has a mean particle size of 1 to 10 ?m, the method comprising the steps of: (a) combining bulk aripiprazole and a vehicle to form a primary suspension; (b) subjecting the primary suspension to first pulverization using e.g., a high shear pulverizing machine, a dispersion machine that applies shear force to a material to be processed, a colloid mill, an ultrasonic dispersion machine, or a high-pressure jet type emulsifying dispersion machine to form a secondary suspension; and (c) subjecting the secondary suspension to second pulverization using e.g., a high pressure jet type emulsifying dispersion machine to form a sterile final suspension; and a method for producing a freeze dried formulation from the aripiprazole suspension.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
The present invention provides a method for treating various diseases with a novel heterocyclic compound represented by Formula [I] and a salt thereof:
The present invention provides a method for treating various diseases with a novel heterocyclic compound represented by Formula [I] and a salt thereof:
The present invention provides a method for treating various diseases with a novel heterocyclic compound represented by Formula [I] and a salt thereof:
wherein the symbols are as defined in the specification, which is useful for treating, preventing and/or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 239/47 - Un atome d'azote et un atome d'oxygène ou de soufre, p. ex. cytosine
C07D 239/54 - Deux atomes d'oxygène liés par une liaison double ou sous forme de radicaux hydroxyle non substitués
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
Provided is a composition in the form of a suspension of submicron particles which is useful as a composition comprising Quabodepistat or a salt thereof, etc. Disclosed, as one example of the composition, is a composition comprising at least one selected from the group consisting of Quabodepistat, salts and co-crystals thereof, and solvates thereof. The composition further comprises a suspending agent and a dispersion medium, and takes the form of a suspension of submicron particles.
Provided is a composition in the form of a suspension of submicron particles, which is useful as a composition containing delamanid or a salt thereof. Disclosed as one embodiment of the composition is a composition which contains delamanid or a salt thereof. The composition contains a suspending agent and a dispersion medium and is in the form of a suspension of submicron particles. The suspending agent comprises at least one member selected from the group consisting of Poloxamers and D-α-tocopherol polyethylene glycol succinates.
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose
20.
MESENCHYMAL CELLS OF VENTRAL HINDGUT MESODERM AND METHOD FOR PRODUCING SAME
This method for producing mesenchymal cells of the ventral hindgut mesoderm comprises: culturing pluripotent stem cells in an induction medium A containing a TGF-β inhibitor, a Wnt agonist, and a fibroblast growth factor to induce differentiation into epiblast-like cells; culturing the epiblast-like cells in an induction medium B containing a Wnt agonist, a fibroblast growth factor, and retinoic acid to induce differentiation into caudal epiblast-like cells; culturing the caudal epiblast-like cells in an induction medium C containing a Wnt agonist, a bone morphogenetic protein, and a TGF-β family member to induce differentiation into posterior primitive streak cells; and culturing the posterior primitive streak cells in an induction medium D containing a Wnt agonist, a fibroblast growth factor, a bone morphogenetic protein, and a hedgehog signaling agonist to induce differentiation into mesenchymal cells of the ventral hindgut mesoderm.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
Provided is a composition in the form of a suspension of microparticles, which is useful as a composition comprising quabodepistat, a salt thereof, or the like. Disclosed as one example of the composition is a composition comprising at least one selected from quabodepistat, a salt thereof, a cocrystal thereof, and solvates of these, wherein the composition contains a suspending agent and a dispersion medium and is in the form of a suspension of microparticles.
A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p. ex. carbazole
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
23.
COMPOSITION FOR PREVENTING OR TREATING DETERIORATION IN BRAIN FUNCTION OR MAINTAINING OR IMPROVING BRAIN FUNCTION
The present invention aims to provide a method for evaluating dementia and a composition for preventing or treating deterioration in brain function, or for maintaining or improving brain function, and compared the gut microbiota of healthy individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease. As a result, gut microorganisms were selected, such as microorganisms belonging to the genus Faecalibacterium, that are associated with cognitive function. Furthermore it was revealed that Faecalibacterium prausnitzii, possessing specific DNA, exhibited an improvement effect against brain function deterioration, such as learning and memory disorders.
A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
24.
PIPERIDINE- AND MORPHOLINE-CARBOXYLATE COMPOUNDS AS SORT1 INHIBITORS
Disclosed are compounds, or salts thereof, with sortilin-binding inhibitory activity, medical use thereof for treating, preventing, and/or diagnosing diseases associated with sortilin ligands, and methods of preparing said compounds, or salts thereof. Provided is a compound of formula (I), or a salt thereof, wherein R1is H, etc.; R21-6 1-6 alkyl, etc.; R322 or O; R41-6 1-6 alkyl; and Ring A is optionally substituted partially unsaturated or unsaturated 7- to 15-membered bicyclic or tricyclic heterocyclyl.
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
05 - Produits pharmaceutiques, vétérinaires et hygièniques
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Diagnostic preparations for medical purposes; diagnostic reagents for medical use Providing medical information; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; pathological testing for diagnostic or treatment purposes.
26.
SHEET-LIKE CELL CULTURE AND METHOD FOR PRODUCING SAME
To provide a method for producing a sheet-like cell culture showing a three-layer structure including a cell layer of superficial cells, a cell layer of intermediate cells, and a cell layer of basal cells, in this order. Provided is a method for producing a sheet-like cell culture that includes culturing a progenitor cell population in a second compartment separated from a first compartment via a porous member to form a sheet-like cell culture in the second compartment. The sheet-like cell culture includes a cell layer of superficial cells derived from the progenitor cell population, a cell layer of intermediate cells derived from the progenitor cell population, and a cell layer of basal cells derived from the progenitor cell population, in this order. The first compartment holds an induction medium containing retinoic acid, bone morphogenetic protein (BMP), and fibroblast growth factor (FGF).
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
A01K 67/0271 - Vertébrés chimériques, p. ex. comprenant des cellules exogènes
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
A61L 27/40 - Matériaux composites, c.-à-d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent
A61P 13/10 - Médicaments pour le traitement des troubles du système urinaire de la vessie
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
Provided is a crystal of a specific oxazole compound that has specific inhibitory activity against PDE4, and that shows excellent stability. Specifically, provided is a crystal of an oxazole compound represented by formula (5)
Provided is a crystal of a specific oxazole compound that has specific inhibitory activity against PDE4, and that shows excellent stability. Specifically, provided is a crystal of an oxazole compound represented by formula (5)
Provided is a crystal of a specific oxazole compound that has specific inhibitory activity against PDE4, and that shows excellent stability. Specifically, provided is a crystal of an oxazole compound represented by formula (5)
wherein the crystal has peaks at diffraction angles 2θ(°) of 9.6±0.2, 19.1±0.2, and 21.2±0.2 in an X-ray powder diffraction pattern measured using Cukα characteristic X-rays.
C07D 263/32 - Composés hétérocycliques contenant des cycles oxazole-1, 3 ou oxazole-1, 3 hydrogéné non condensés avec d'autres cycles comportant deux ou trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
An object of the present invention is to provide a sustained-release injectable preparation which is in a medication administration form that can provide the effect of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, which releases the active ingredient in such a manner that its blood concentration is maintained for at least one week.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
Pharmaceutical preparations for the treatment of central nervous system diseases and disorders, containing electronic chips which transmit information about drug ingestion by the patient Computer application software for mobile phones, tablets, portable electronic devices and handheld computers for use in collecting and storing patient data and medical information including drug ingestion information, pulse, heart rate, respiratory rate, body temperature, electric pressure in the body, human motion, human position or sleeping condition from a sensor attached to the patient's body. Sensor patches attached to the patient's body for use in measuring, collecting and storing patient data and medical information including drug ingestion information, pulse, heart rate, respiratory rate, body temperature, electric pressure in the body, human motion, human position or sleeping condition.
Provided is a computer program, an information processing device, and a method that are used to estimate a health state of a target user based on a history of behaviors executed by the target user, and have at least partially improved performance.
Provided is a computer program, an information processing device, and a method that are used to estimate a health state of a target user based on a history of behaviors executed by the target user, and have at least partially improved performance.
According to one embodiment, a computer program can cause, by being executed at least one processor, the at least one processor to function to: acquire target behavior data for identifying a history of behavior executed by a target user; and output, from an estimation model generated by executing supervised learning, target sleep state data for identifying a sleep state of the target user, the target sleep state data including at least one of target property data for identifying a sleep property of the target user, target rhythm data for identifying a sleep rhythm of the target user, target time data for identifying a sleep time of the target user, and target category data for identifying a sleep category to which the target user belongs, by inputting the target behavior data to the estimation model.
G16H 20/60 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant le contrôle de l’alimentation, p. ex. les régimes
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
33.
COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER
The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.
A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
A61K 31/4525 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'oxygène comme hétéro-atome du cycle
A61K 31/5513 - 1,4-Benzodiazépines, p. ex. diazépam
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
Produits et services
Soap; cosmetic soaps; dentifrices; toilet water; lotions for
cosmetic purposes; skin lotion; hair lotion; body lotion;
wave-set lotions; perfumery, other than perfumes for
personal use; incense; false nails; false eyelashes.
35.
PROCESSES FOR MAKING INTERMEDIATES FOR ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY
The present disclosure relates to processes for preparing synthetic intermediates for the synthesis of isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity.
C07D 309/06 - Radicaux substitués par des atomes d'oxygène
C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07F 7/18 - Composés comportant une ou plusieurs liaisons C—Si ainsi qu'une ou plusieurs liaisons C—O—Si
Provided is a novel chimeric antigen receptor. This chimeric antigen receptor includes an scFv region having such a structure that the C-terminus of a heavy-chain variable region and the N-terminus of a light-chain variable region are linked to each other through a linker, wherein: the heavy-chain variable region includes a heavy-chain CDR1 having the amino acid sequence represented by SEQ ID NO: 1, a heavy-chain CDR2 having the amino acid sequence represented by SEQ ID NO: 2, and/or a heavy-chain CDR3 having the amino acid sequence represented by SEQ ID NO: 3, and/or the light-chain variable region includes a light-chain CDR1 having the amino acid sequence represented by SEQ ID NO: 5, a light-chain CDR2 having the amino acid sequence represented by SEQ ID NO: 6, and/or a light-chain CDR3 having the amino acid sequence represented by SEQ ID NO: 7; and the number of amino acid residues constituting the linker is 15-50.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
C12N 15/12 - Gènes codant pour des protéines animales
The present disclosure relates to pharmaceutical compositions comprising a solid dispersion comprising a compound of Formula (I): (I), or a pharmaceutically acceptable salt thereof, as well as methods of treatment.
This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan from the gastrointestinal tract; and a solid formulation for oral administration that can be suspended to prepare the suspension for oral administration at the time of use. This invention relates to a suspension for oral administration, in particular, a syrup, comprising (a) particles containing amorphous tolvaptan, (b) hydroxypropyl methylcellulose (HPMC), and (c) a solvent, wherein the amount of the HPMC (b) is 0.1 to 25% by weight based on the total weight of the suspension for oral administration.
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A combination of antitumor agents significantly shrinks tumors by synergistic antitumor action without increasing side effects to the extent possible. The antitumor composition contains compound (B) or a salt thereof for use in combination with antitumor agent (A), where (A) is at least one antitumor agent selected from alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors; and (B) is a compound or a salt thereof represented by formula (1):
A combination of antitumor agents significantly shrinks tumors by synergistic antitumor action without increasing side effects to the extent possible. The antitumor composition contains compound (B) or a salt thereof for use in combination with antitumor agent (A), where (A) is at least one antitumor agent selected from alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors; and (B) is a compound or a salt thereof represented by formula (1):
A combination of antitumor agents significantly shrinks tumors by synergistic antitumor action without increasing side effects to the extent possible. The antitumor composition contains compound (B) or a salt thereof for use in combination with antitumor agent (A), where (A) is at least one antitumor agent selected from alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors; and (B) is a compound or a salt thereof represented by formula (1):
where R1 is halogen, aryl, aryloxy, or lower alkyl optionally substituted with one or more halogen atoms; R2 is hydrogen, halogen, lower alkyl, or lower alkoxy; and m=1 to 3, provided that when m is 2 or 3, each R1 is the same or different.
Disclosed are pyrazolopyridine or pyrazolopyrimidine compounds, or salts thereof, with colony-stimulating factor-1 receptor (CSF1R) inhibitory activity, medical use thereof for treating, preventing, and/or diagnosing diseases associated with CSF1R, and methods of preparing said compounds, or salts thereof. Provided include a compound represented by Formula [I], or a salt thereof, wherein R1is hydrogen, etc.; R21and R22are hydrogen, or R21and R22together with the adjacent heterocyclic form a bridged bicyclic ring; R3is -L31-R31optionally substituted with one or more R32, or R31optionally substituted with one or more R32; L31is -C(=O)-, etc.; R311-61-6 alkyl, etc.; R32is each independently halogen, etc.; and X is CR1 or N; medical use thereof, and methods of preparation thereof.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention discloses administering pharmaceutical compositions in combination, one of which is a pharmaceutical composition containing a tolinapant drug, and the other of which is a pharmaceutical composition containing an immune cell modified to express a chimeric antigen receptor or a recombinant T-cell receptor.
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
A compound represented by formula [I]:
A compound represented by formula [I]:
A compound represented by formula [I]:
wherein R12, R13, R14, R15, and R16 are the same or different and are each hydrogen, halogen, C1-6 alkyl optionally substituted with halogen, or C1-6 alkoxy optionally substituted with halogen; R21, R22, and R23 are the same or different and are each hydrogen, halogen, C1-6 alkyl optionally substituted with halogen, C1-6 alkoxy optionally substituted with halogen, sulfanyl optionally substituted with halogen, nitro, or cyano; R3 is C1-6 alkyl or the like; and X− is an anion.
C07D 219/04 - Composés hétérocycliques contenant les systèmes cycliques de l'acridine ou de l'acridine hydrogénée avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du système cyclique
B01J 31/02 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des composés organiques ou des hydrures métalliques
C07C 37/60 - Préparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone d'un cycle aromatique à six chaînons par des réactions d'oxydation introduisant directement des groupes hydroxyle sur un groupe CH appartenant à un cycle aromatique à six chaînons avec d'autres oxydants que l'oxygène moléculaire ou des mélanges d'oxygène moléculaire et d'oxydant
Provided is a means that is capable of preventing initial excessive release of an active ingredient, and that allows for sustained release of a pharmaceutically active amount of the active ingredient over a long period of time.
An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s−1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s−1, as measured.
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; pharmaceutical preparations for
the treatment of central nervous system diseases and
disorders.
49.
PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF
The present invention relates to a prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease, which contains 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient.
Provided is a solution suitable for oral administration of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one(compound (I)) or a salt thereof. A solution for oral administration containing compound (I) or a salt thereof, and at least one compound selected from the group consisting of lactic acid, phosphoric acid, glycolic acid, malic acid, tartaric acid, citric acid, succinic acid and acetic acid and having pH 2.5-4.5.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
Provided is a heat shock protein expression-inducing agent, more specifically, a heat shock protein expression-inducing agent comprising a compound represented by formula (I):
Provided is a heat shock protein expression-inducing agent, more specifically, a heat shock protein expression-inducing agent comprising a compound represented by formula (I):
Provided is a heat shock protein expression-inducing agent, more specifically, a heat shock protein expression-inducing agent comprising a compound represented by formula (I):
wherein R is a lower alkyl, phenyl, or hydroxyphenyl, or a salt thereof.
Medical apparatus and instruments for use in diagnosing and monitoring vital signs of patients with psychiatric and neurological disorders and diseases, dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, migraine, pain, alcoholism and dependency; injection devices for medical purposes; syringes and needles for injections and medical purposes; apparatus and instruments for diagnostic purposes, namely, integrated medical systems comprising medical diagnostic imaging apparatus and software sold as a unit therewith for managing, measuring, monitoring, assessing, controlling, collecting, storing, and examining patient and client data and information captured by the medical system in web-based physical, psychological and neurological examinations conducted at a distance and at a clinic; medical apparatus and units for dosage, measuring and monitoring, namely, drug delivery devices and systems
An object of the present invention is to provide a freeze-dried aripiprazole powder formulation that exhibits good dispersibility and is easily dispersed into a homogenous suspension when reconstituted with water. The present invention provides a freeze-dried aripiprazole formulation obtained by a process comprising the steps of spraying for freezing an aripiprazole suspension containing (I) aripiprazole, (II) a vehicle for the aripiprazole, and (III) water for injection, and drying
A61K 9/28 - DragéesPilules ou comprimés avec revêtements
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 31/453 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'oxygène comme hétéro-atome du cycle
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
Provided is a means that is capable of preventing initial excessive release of an active ingredient and that allows for sustained release of the active ingredient in a pharmaceutically active amount over a long period of time.
A novel means for improving sleep quality etc. is provided. Provided is a composition for sleep quality improvement that contains kaempferol and/or a glycoside thereof.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
Provided are novel benzazepine compounds of Formula (1), or salts thereof, having vasopressin V1a and V2 antagonisms, and medical uses thereof,
Provided are novel benzazepine compounds of Formula (1), or salts thereof, having vasopressin V1a and V2 antagonisms, and medical uses thereof,
Provided are novel benzazepine compounds of Formula (1), or salts thereof, having vasopressin V1a and V2 antagonisms, and medical uses thereof,
in the formula, R1 is optionally substituted C1-6 alkyl, etc.; L is —C(═O)—NH—, etc.; Ring A1 is a hydrocarbon ring, etc.; Ring A2 is a hydrocarbon ring, etc.; and each of Rings A1 and A2 may have at least one substituent.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 401/10 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques
The present application provides a phytin with improved solubility in water, wherein the phytin comprises calcium and/or magnesium with specific of molar ratios to phytic acid.
Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.
A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p. ex. carbazole
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
66.
PHARMACEUTICAL COMPOSITIONS INCLUDING TOLINAPANT AND PACKAGING
The present disclosure relates generally pharmaceutical compositions comprising tolinapant or a pharmaceutically acceptable salt thereof, as well as methods of treatment, and packaging of the dosage form.
The disclosure provides a frozen dessert composition including (A) about 6 to 15% by weight of palatinose based on the total weight of the composition, and (B) about 10 to 30% by weight of a dextrin or a combination of a dextrin and a soluble dietary fiber based on the total weight of the composition. The disclosure also provides a method of manufacturing a frozen dessert composition including mixing the following components with water; (A) about 6 to 15% by weight of palatinose based on the total weight of the composition, and (B) about 10 to 30% by weight of a dextrin or a combination of a dextrin and a soluble dietary fiber based on the total weight of the composition.
A23G 9/34 - Desserts glacés, p. ex. confiseries glacées, glacesMélanges correspondants caractérisés par la composition caractérisés par les hydrates de carbone utilisés, p. ex. des polysaccharides
A23G 9/38 - Desserts glacés, p. ex. confiseries glacées, glacesMélanges correspondants caractérisés par la composition contenant des peptides ou des protéines
A23L 33/21 - Adjonction de substances essentiellement non digestibles, p. ex. de fibres diététiques
B65D 85/60 - Réceptacles, éléments d'emballage ou paquets spécialement adaptés à des objets ou à des matériaux particuliers pour bonbons ou confiseries analogues
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Anti-psychotics; central nervous system stimulants; central nervous system depressants; pharmaceutical preparations for the treatment of schizophrenia; pharmaceutical preparations for the treatment of bipolar disorder; pharmaceutical preparations for the treatment of irritability associated with autistic disorder.
71.
COMPOSITION FOR TREATING AND/OR PREVENTING HEARING IMPAIRMENT
Provided is: a composition for treating and/or preventing hearing impairment, the composition containing an asparagus extract; or a composition for maintaining and/or improving hearing function, the composition containing an asparagus extract.
The present invention relates to a safe and effective therapeutic agent for nonalcoholic steatohepatitis (NASH), more specifically, a therapeutic, preventative and/or diagnostic medicament for NASH, comprising 5-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-3H-[1,2,3]triazole-4-carbonitrile, represented by the following structural formula or a pharmaceutically acceptable salt thereof.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
Provided is a composition comprising delamanid particles for which the formation of secondary particles is suppressed. Specifically, provided is a composition comprising (A) delamanid particles and (B) a surface stabilizer.
The present invention provides a novel compound having an excellent antitumor effect, stability and metabolic stability. The compound of the present invention is represented by the following general formula (1) wherein R1 represents a halogen atom, an aryl group, an aryloxy group or a lower alkyl group optionally substituted with one or more halogen atoms; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; and; m represents an integer of 1 to 3; provided that when m represents 2 or 3, R1s are the same or different.
The present invention provides a novel compound having an excellent antitumor effect, stability and metabolic stability. The compound of the present invention is represented by the following general formula (1) wherein R1 represents a halogen atom, an aryl group, an aryloxy group or a lower alkyl group optionally substituted with one or more halogen atoms; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; and; m represents an integer of 1 to 3; provided that when m represents 2 or 3, R1s are the same or different.
C07D 213/75 - Radicaux amino ou imino, acylés par un acide carboxylique, par l'acide carbonique ou par leurs analogues du soufre ou de l'azote, p. ex. des carbamates
C07D 213/76 - Atomes d'azote auxquels est lié un second hétéro-atome
Provided is a therapeutic agent for ADHD having an efficacy comparable to that of central nervous system stimulants and the same low risk of drug dependence and abuse as existing non-central nervous system stimulants, more particularly a compound represented by formula [I]:
Provided is a therapeutic agent for ADHD having an efficacy comparable to that of central nervous system stimulants and the same low risk of drug dependence and abuse as existing non-central nervous system stimulants, more particularly a compound represented by formula [I]:
Provided is a therapeutic agent for ADHD having an efficacy comparable to that of central nervous system stimulants and the same low risk of drug dependence and abuse as existing non-central nervous system stimulants, more particularly a compound represented by formula [I]:
wherein each symbol is as defined in the description, or a salt thereof.
C07D 241/42 - Benzopyrazines avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone de l'hétérocycle
A61K 31/498 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinoxaline, phénazine
The present invention provides an agent for treating malignant tumor, comprising a compound of formula (1):
The present invention provides an agent for treating malignant tumor, comprising a compound of formula (1):
wherein R1 to R4 are hydrogen atom, halogen, or etc., Y is optionally-substituted alkylene group or etc.
C07D 237/04 - Composés hétérocycliques contenant des cycles diazine-1, 2 ou diazine-1, 2 hydrogéné non condensés avec d'autres cycles comportant moins de trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of immunoglobulin A nephropathy (IgAN); pharmaceutical preparations for treatment of autoimmune diseases and disorders.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of immunoglobulin A nephropathy (IgAN); pharmaceutical preparations for treatment of autoimmune diseases and disorders.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of central nervous system diseases and disorders; pharmaceutical preparations for the treatment of attention deficit hyperactivity disorder, binge eating disorder and major depressive disorder; pharmaceutical preparations, namely, smoking cessation preparations.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations for the treatment of attention deficit hyperactivity disorder; pharmaceutical preparations for the prevention and treatment of smoking habits and addictions.
83.
PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS
Provided is a pyrazolo[1,5-a]pyrimidine compound represented by the general formula [I]:
Provided is a pyrazolo[1,5-a]pyrimidine compound represented by the general formula [I]:
Provided is a pyrazolo[1,5-a]pyrimidine compound represented by the general formula [I]:
wherein each symbol is as defined in the description, or a salt thereof, having PAR2 inhibitory activity, and a pharmaceutical composition comprising the same.
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/541 - Thiazines non condensées contenant d'autres hétérocycles
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
A61K 31/553 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. loxapine, staurosporine
A technique calls attention for a subject to a predetermined disease or to a disorder that is accompanied by a symptom obstructing the subject's daily life. An information providing method includes acquiring personal data of a target customer, determining a segmentation to which the customer belongs based on the data and a classification criterion that is prepared in advance, from plural segmentations each indicating a class that corresponds to the degree of a health condition, and providing health information that corresponds to the segmentation to the customer. The personal data includes pieces of unique data on the target customer. At least one of the pieces of unique data is symptom data that reflects a health symptom of the target customer. The segmentations are classified corresponding to the degrees of the health symptom, and each of the segmentations is correlated with health information prepared in advance corresponding to the health symptom.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G16H 80/00 - TIC spécialement adaptées pour faciliter la communication entre les professionnels de la santé ou les patients, p. ex. pour le diagnostic collaboratif, la thérapie collaborative ou la surveillance collaborative de l’état de santé
85.
METHODS FOR DOSE INITIATION OF ARIPIPRAZOLE TREATMENTS
The present disclosure is directed to a method of dose initiation for an aripiprazole treatment to a patient in need thereof; the patient is administered two, separate 100 to 500 mg injections of an aripiprazole intramuscular (IM) depot formulation at separate gluteal and/or deltoid injection sites, and a single dose of oral aripiprazole. The administration occurs on a first day of the treatment.
An object of the present invention is to a new method of producing a kidney organoid. The method for producing a kidney organoid is characterized by comprising culturing an early kidney organoid with a medium containing an RXR agonist and a PPAR agonist, wherein the kidney organoid includes matured proximal tubule cells.
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
A61K 35/22 - UrineAppareil urinaire, p. ex. rein ou vessieCellules mésangiales intraglomérulairesCellules mésenchymateuses rénalesGlande surrénale
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
87.
INHIBITOR OF MEGAKARYOCYTE DIFFERENTIATION AND MATURATION
The present invention relates to a compound of formula (I) which can selectively inhibit the differentiation from hematopoietic stem cell toward megakaryocytes.
The invention provides a compound of formula (0):
The invention provides a compound of formula (0):
or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein:
n is 1 or 2;
X is CH or N;
Y is selected from CH and C—F;
Z is selected from C—Rz and N;
R1 is selected from:
-(Alk1)t-Cyc1; wherein t is 0 or 1;
Optionally substituted C1-6 acyclic hydrocarbon groups
R2 is selected from hydrogen; halogen; and C1-8 hydrocarbon groups optionally substituted with one or more fluorine atoms;
R3 is hydrogen or a group L1-R7;
R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and
R4a is selected from hydrogen and a C1-3 alkyl group;
wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein;
provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.
The invention provides a compound of formula (0):
or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein:
n is 1 or 2;
X is CH or N;
Y is selected from CH and C—F;
Z is selected from C—Rz and N;
R1 is selected from:
-(Alk1)t-Cyc1; wherein t is 0 or 1;
Optionally substituted C1-6 acyclic hydrocarbon groups
R2 is selected from hydrogen; halogen; and C1-8 hydrocarbon groups optionally substituted with one or more fluorine atoms;
R3 is hydrogen or a group L1-R7;
R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and
R4a is selected from hydrogen and a C1-3 alkyl group;
wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein;
provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.
The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/541 - Thiazines non condensées contenant d'autres hétérocycles
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 31/553 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. loxapine, staurosporine
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 498/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle dans lesquels le système condensé contient au moins quatre hétérocycles
An ointment is provided. The ointment stably comprises an oxazole compound that has specific inhibitory activity against PDE4 and that is represented by the following formula (11). The ointment can be efficiently absorbed into the skin.
An ointment is provided. The ointment stably comprises an oxazole compound that has specific inhibitory activity against PDE4 and that is represented by the following formula (11). The ointment can be efficiently absorbed into the skin.
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
C07D 263/32 - Composés hétérocycliques contenant des cycles oxazole-1, 3 ou oxazole-1, 3 hydrogéné non condensés avec d'autres cycles comportant deux ou trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
Provided is a novel therapeutic agent for central nervous system diseases. More specifically, provided is a compound represented by formula (I) (in the formula, R1and R2each independently denote -Oi, -OR4or -NR4NaR4Nb, R3denotes hydrogen or an alkyl group, R4, R4Naand R4Nb22-) in alkyl groups denoted by R4, R4Naand R4Nbmay be replaced by -O-, -S-, -CO-, -NH-, -SiRsiaRsib- or -(CO)O-, and in a case where R1and R2both denote -OR4, R1and R2may be the same as, or different from, each other, and in a case where R1and R2both denote -NR4NaR4Nb, R1and R2 may be the same as, or different from, each other), or a salt of said compound.
C07F 9/6561 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle contenant des systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un carbocycle ou un système carbocyclique commun, avec ou sans autres hétérocycles non condensés
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
91.
RESPONSE-BASED DOSING FOR TREATING CANCER WITH A HYPOMETHYLATING AGENT AND CEDAZURIDINE
Provided according to some embodiments of the invention are methods of treating cancer in a subject in need thereof that include administering to the subject a first amount of a hypomethylating agent (e.g., decitabine) and a first amount of cedazuridine in a first dosing cycle; measuring a response of the cancer to the first dosing cycle; and administering a second, reduced amount of the hypomethylating agent and a second, reduced amount of cedazuridine in subsequent dosing cycle(s) if the response of the cancer to the first dosing cycle meets a predetermined criterion.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
C07D 405/02 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles
C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
The present disclosure is directed to methods of dose initiation for an aripiprazole treatment to a patient in need thereof by administering two, separate injections of aripiprazole with a first aripiprazole injection of a long acting injectable (LAI) and a second aripiprazole injection of a once-monthly injectable (AOM) on a first day of the aripiprazole treatment, and a single dose of oral aripiprazole. Maintenance dosing occurs about two months after the first day of the aripiprazole treatment using a maintenance dose of the LAI. The present methods are applicable to both the deltoid and gluteal administration sites.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of immunoglobulin A nephropathy (IgAN); pharmaceutical preparations for treatment of autoimmune diseases and disorders.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of immunoglobulin A nephropathy (IgAN); pharmaceutical preparations for treatment of autoimmune diseases and disorders.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of immunoglobulin A nephropathy (IgAN); pharmaceutical preparations for treatment of autoimmune diseases and disorders.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of immunoglobulin A nephropathy (IgAN); pharmaceutical preparations for treatment of autoimmune diseases and disorders.
The present invention provides a production method for megakaryocytes that includes a step for forcing hematopoietic precursor cells to express a cancer gene, a homeobox gene, and an apoptosis-suppressing gene and culturing the cells. The present invention also provides a kit for producing megakaryocytes, mature megakaryocytes, or platelets that includes a vector that includes a cancer gene, a homeobox gene, and an apoptosis-suppressing gene.
